LONG-TERM PERSISTENCE OF METABOLIC ABNORMALITIES IN ABSORPTIVE OR RENAL HYPERCALCIURIA

CharlesY C. Pak, MichaelJ Nicar

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Seven patients with absorptive hypercalciuria and seven with renal hypercalciuria were re-evaluated 1·67-7·33 years after the original diagnosis. When treatment was temporarily stopped, all showed the same metabolic abnormalities as before: those with absorptive hypercalciuria continued to show increased intestinal absorption of calcium and normal or suppressed parathyroid function, and those with renal hypercalciuria had persistent "renal leak" of calcium and parathyroid stimulation. In view of the persistence of metabolic abnormalities, medical therapy should be regarded as a long-term commitment.

Original languageEnglish (US)
Pages (from-to)356-359
Number of pages4
JournalThe Lancet
Volume317
Issue number8216
DOIs
StatePublished - Feb 14 1981

Fingerprint

Hypercalciuria
Kidney
Calcium
Intestinal Absorption
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

LONG-TERM PERSISTENCE OF METABOLIC ABNORMALITIES IN ABSORPTIVE OR RENAL HYPERCALCIURIA. / Pak, CharlesY C.; Nicar, MichaelJ.

In: The Lancet, Vol. 317, No. 8216, 14.02.1981, p. 356-359.

Research output: Contribution to journalArticle

@article{17ac13436f9b4e5bb3ce479221a63a48,
title = "LONG-TERM PERSISTENCE OF METABOLIC ABNORMALITIES IN ABSORPTIVE OR RENAL HYPERCALCIURIA",
abstract = "Seven patients with absorptive hypercalciuria and seven with renal hypercalciuria were re-evaluated 1·67-7·33 years after the original diagnosis. When treatment was temporarily stopped, all showed the same metabolic abnormalities as before: those with absorptive hypercalciuria continued to show increased intestinal absorption of calcium and normal or suppressed parathyroid function, and those with renal hypercalciuria had persistent {"}renal leak{"} of calcium and parathyroid stimulation. In view of the persistence of metabolic abnormalities, medical therapy should be regarded as a long-term commitment.",
author = "Pak, {CharlesY C.} and MichaelJ Nicar",
year = "1981",
month = "2",
day = "14",
doi = "10.1016/S0140-6736(81)91674-3",
language = "English (US)",
volume = "317",
pages = "356--359",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "8216",

}

TY - JOUR

T1 - LONG-TERM PERSISTENCE OF METABOLIC ABNORMALITIES IN ABSORPTIVE OR RENAL HYPERCALCIURIA

AU - Pak, CharlesY C.

AU - Nicar, MichaelJ

PY - 1981/2/14

Y1 - 1981/2/14

N2 - Seven patients with absorptive hypercalciuria and seven with renal hypercalciuria were re-evaluated 1·67-7·33 years after the original diagnosis. When treatment was temporarily stopped, all showed the same metabolic abnormalities as before: those with absorptive hypercalciuria continued to show increased intestinal absorption of calcium and normal or suppressed parathyroid function, and those with renal hypercalciuria had persistent "renal leak" of calcium and parathyroid stimulation. In view of the persistence of metabolic abnormalities, medical therapy should be regarded as a long-term commitment.

AB - Seven patients with absorptive hypercalciuria and seven with renal hypercalciuria were re-evaluated 1·67-7·33 years after the original diagnosis. When treatment was temporarily stopped, all showed the same metabolic abnormalities as before: those with absorptive hypercalciuria continued to show increased intestinal absorption of calcium and normal or suppressed parathyroid function, and those with renal hypercalciuria had persistent "renal leak" of calcium and parathyroid stimulation. In view of the persistence of metabolic abnormalities, medical therapy should be regarded as a long-term commitment.

UR - http://www.scopus.com/inward/record.url?scp=0019363429&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019363429&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(81)91674-3

DO - 10.1016/S0140-6736(81)91674-3

M3 - Article

VL - 317

SP - 356

EP - 359

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 8216

ER -